Allogeneic stem cell transplantations (SCT) are currently being used as a therapy for hematological malignancies, some solid tumors and nonmalignant bone marrow deficiencies. Nevertheless, clinical applicability is limited due to toxicity of conditioning regimens, graft-versus-host disease (GVHD) and the scarcity of HLA-identical family donors. New concepts are based on nonmyeloablative conditioning to reduce toxicity, prevention or amelioration of GVHD and the use of haploidentical donors to increase donor availability. To combine these requirements, we have developed a nonmyeloablative conditioning regimen, consisting of low-dose total body irradiation and cyclophosphamide-based chemotherapy. In a haploidentical F1-F1 mouse model, this nonmyeloablative transplantation protocol resulted in stable full donor chimerism, but also in the development of severe GVHD. Administration of keratinocyte growth factor (KGF) reduced GVHD, evident as reduced weight loss and a lesser degree of dermatitis, compared to saline-treated controls. KGF preserved plasma citrulline and tumor necrosis factor-a levels, both indicative for reduced injury to the gastrointestinal tract. This was confirmed by histological findings. At 6 months after transplantation, survival rates were significantly higher in KGF-treated animals as compared to phosphate buffered saline-treated controls. These results indicate that KGF preserves gut integrity and might therefore contribute substantially to reduction of lethal GVHD in (nonmyeloablative) haploidentical transplantation. Bone Marrow Transplantation (2005) 36, 907-915.
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Another obstacle limiting clinical applicability is the availability of HLA-identical family donors. Patients have indeed less than 30% chance of finding a fully matched sibling donor and are therefore often dependent on unrelated BM donors. Even then, a suitable donor cannot be found for a considerable percentage of Caucasian patients. Other ethnic groups that are more polymorphic with respect to HLA are even less likely to find a donor. 1 On the other hand, virtually every patient has a family member who shares one HLA haplotype, but is mismatched for the other. For this criterion, children, both parents and 50% of siblings qualify, thereby dramatically increasing the availability of potentially suitable BM.
Regrettably, haploidentical transplantations are associated with an increased risk of toxicity and the development of GVHD due to the immunological barrier between donor and recipient and the intensive conditioning regimen needed to overcome it. 2, 3 Myeloablative conditioning does in fact damage and activate host tissues that in turn secrete inflammatory cytokines, leading to a cytokine cascade and subsequent development of GVHD. 4 Throughout transplantation history, nonmyeloablative conditioning regimens have been developed with the aim to reduce toxicity and decrease transplant-related morbidity and mortality. These nonmyeloablative transplantation protocols not only prevented post-transplant immunodeficiency, they also reduced GVHD. [5] [6] [7] However, apart from some case reports [8] [9] [10] and smaller studies, [11] [12] [13] the use of nonmyeloablative conditioning has not extensively been reported for haploidentical donor-recipient combinations.
As it has been shown that alloreactive T cells in the donor graft are responsible for the induction of GVHD, extensive T cell depletion (TCD) of the BM inoculum has been proven effective in its prevention and so far, haploidentical transplantations are possible only after this type of intervention. However, an increased risk of relapse, infection and graft failure was observed following transplantations with TCD BM, indicating that T cell responses are necessary for engraftment, immune recovery and antitumor effects. 3, [14] [15] [16] Some therapeutic models have used these T cell-mediated reactions to their advantage and applied alloreactive T cells to kill residual tumor and BM cells, allowing less severe preparative conditioning. [17] [18] [19] Alternatively, restoring T cells after transplantation has been suggested as a valuable option to prevent the side effects of T cell depletion. 20 Other experimental approaches to reduce GVHD, such as induction of oral tolerance 21 or treatment with donor regulatory T cells, 22 dendritic cells 23 and NK cells, 24 are currently under investigation as well.
Another GVHD prophylaxis that has been proven effective in transplantation models with non-TCD BM is keratinocyte growth factor (KGF). KGF is a member of the fibroblast growth factor family, also designated as FGF-7, that specifically influences epithelial cells in vivo and in vitro.
25 KGF induces proliferation in keratinocytes, 26 type II pneumocytes, 27 hepatocytes and gastrointestinal (GI) epithelial cells. 28 It has also been demonstrated that KGF can enhance survival of crypt stem cells 29 and might thus be used to protect the GI mucosa when administered prior to conditioning. Other researchers have demonstrated that KGF also exhibits a protective effect independent of conditioning-induced injury. 30 In mouse models of allogeneic BM transplantation, it was shown that KGF treatment reduced GVHD severity and increased survival 31 without the impairment of the graft-versus-leukemia effect. 32 It has to be noted that these studies have described lethal conditioning regimens and either fully mismatched mouse combinations or parent to F1 transplantations.
The purpose of our investigation was to develop a haploidentical, nonmyeloablative transplantation model, capable of inducing stable chimerism and to study whether GVHD in such a model could be ameliorated or prevented by KGF. The present study provides evidence that in this particular setting, KGF treatment not only reduces GVHD but also improves survival of animals receiving a haploidentical allogeneic SCT using a nonmyeloablative conditioning regimen. ) hybrid mice were purchased from Harlan Netherlands (Horst, The Netherlands). Animals were 7 or 8 weeks of age and were used as recipients and donors, respectively. Mice were housed in the animal facility of the University of Maastricht and were allowed normal rodent chow and water ad libitum. All experiments were approved by the Animal Ethical Committee of the University of Maastricht.
Materials and methods

Mice
Conditioning regimen
In developing the model, animals received a single total body irradiation (TBI) dose of 600 or 400 cGy 1 day before transplantation (day À1) or two fractions of 200 cGy with 24 h interval on days À2 and À1. TBI was combined with 150 or 200 mg/kg cyclophosphamide (Cy) intraperitoneally (i.p.) on day À1. In all experiments with KGF treatment, animals were conditioned with two fractions of 200 cGy TBI on days À2 and À1 and 200 mg/kg Cy on day À1. Animals were placed in a Perspex container, without anesthesia and radiation was delivered by a PHILIPS X-ray unit (225 kV, 10 mA) at a dose rate of 66 cGy/min. Cy (Endoxan 1 g, Baxter) was obtained from the hospital's pharmacy and further diluted according to the manufacturer's instructions.
Preparation of cell suspensions and SCT
Femora and tibiae of B6CBAF1 donor mice were flushed with RPMI 1640 (Life Technologies, Breda, The Netherlands) using a 25 G needle. Spleens and flushed marrow were filtered through nylon mesh screens to obtain singlecell suspensions. One day after termination of conditioning (day 0), CB6F1 recipient mice were injected i.v. with 3.3 Â 10 7 donor BM and 1 Â 10 8 unseparated splenocytes.
KGF treatment
Recombinant human KGF (palifermin) was provided by Amgen Inc. (Thousand Oaks, CA, USA) and dissolved in the supplied reconstitution fluid. Further dilutions were made in phosphate-buffered saline (PBS) (Life Technologies, Breda, The Netherlands) before injection. Experimental mice were injected subcutaneously with 5 mg/kg/ day, and control mice received 200 ml PBS. Treatment started 3 days before conditioning (day À5) and was continued till 3 days after transplantation (day þ 3).
GVHD monitoring
Animals were monitored daily for clinical signs of GVHD, that is, weight loss, diarrhea, changes in fur and skin texture and hunched posture. As diarrhea was not a common symptom in these experiments, the traditional score for GVHD in animals could not be applied in our model. In addition to the registration of changes in weight, we applied a scoring system based on dermatitis alone, as it was the most distinct symptom in our experiments. The absence of dermatitis resulted in a score of 0, whereas mild cases of dermatitis, covering less than 50% of the body surface and restricted to the ears or extremities, received a score of 1. When dermatitis covered 50% of the body, a score of 2 was applied to indicate an intermediate form.
Animals with a severe form of dermatitis, covering over 50% of the body surface and resulting in alopecia, received a score of 3.
Flow cytometry
To determine chimerism, peripheral blood was collected by orbital puncture, using heparinized capillaries and suspended in PBS (Life Technologies). supplemented with 0.1% fetal calf serum (FCS) (Greiner Bio-One GmbH, Frickenhausen, Germany) and 0.02% sodium azide (Merck, Darmstadt, Germany). After preincubation with mouse Fc block for 10 min, cells were incubated with
k or rat-anti-mouse CD19 and PE-Cy5-labeled rat-anti-mouse CD3, for 30 min on ice. All antibodies were purchased from BD Biosciences/Pharmingen (San Diego, CA, USA). After staining, cells were washed and remaining erythrocytes were lysed by means of FACS Lysing Solution (BD). Analysis was performed on a FACSsort cytometer (BD).
Plasma citrulline levels
A measure of 0.2 ml of whole blood was collected by orbital puncture and centrifuged at 8900 g for 5 min at 41C to obtain plasma. To determine the amino-acid levels, 50 ml of plasma was added to 4.5 mg dry 5-sulfosalicylic acid, vortexed, frozen in liquid nitrogen and stored at À801C until analysis. Plasma amino-acid concentrations were measured using high-performance liquid chromatography, as described previously. 33 
TNF-a enzyme-linked immunosorbent assay (ELISA)
Mouse TNF-a levels in plasma were determined by ELISA as described previously. 34 TNF-a ELISA's were kindly provided by Professor WA Buurman (Department of Surgery, University of Maastricht, Maastricht, The Netherlands).
Histology
Small bowel tissue samples were fixed in 4% formalin, processed through graded alcohol and embedded in paraffin. Sections (3 mm) were stained with hematoxylin and eosin (H&E) for histologic examination. Slides were coded and scored blindly for signs of GVHD, defined as single-cell necrosis, disintegration of crypts and cellular infiltration. Four sections with an interval of 60 mm were investigated. Semiquantitavive measurements were used to distinguish between more and less GVHD: 0: no lesions; 1: less than 10 necrotic cells per four sections; 2: less than 10 necrotic cells per section; 3: more than 10 individual necrotic cells per section; and 4: more than 10 individual necrotic cells per section and disintegration of the crypts.
Morphometry
Morphometric analysis of small bowel samples was performed as described previously. 35 Briefly, three digitized images per mouse at Â 20 magnification were evaluated using the calibrated image analysis system (Leica Quantimet 570 C; Leica Qwin Pro V 2.8). After digital substraction of intraluminal contents, the epithelial surface lining was demarcated and measured as a perimetrical length. Adjacent villar surfaces were digitally separated to enable measurement of the epithelial surface lining for individual villi. The sum of the perimetrical lengths (mm) represents the total epithelial surface lining per transverse section. For statistical analysis, the mean averaged score of three images per mouse was used.
Statistics
Results were analyzed according to the Student's unpaired t-test. Values are presented as mean7s.e.m. For statistical analysis of TNF-a values and dermatitis scores, the MannWhitney test was used. Survival curves were composed using the Kaplan-Meier method and compared with the Mantel-Cox log-rank test. Differences in survival 200 days after transplantation were analyzed with the Fisher's exact test. To calculate the correlation between the mucosal surface and the citrulline values, the Pearson's correlation test was used. In all cases, differences were considered statistically significant when probability (P) values were less than or equal to 0.05.
Results
Development of the model
To establish a nonmyeloablative transplantation model resulting in stable donor chimerism, different conditioning protocols were tested. Initial regimens consisting of a single TBI dose of 850 cGy or a combination of 600 cGy and 200 mg/kg Cy were lethal without BM rescue. As animals died in an anemic state due to bone marrow failure within 14 days after conditioning, these regimens were considered unsuitable. Subsequent experiments used conditioning regimens in which either the radiation dose or the amount of chemotherapy was reduced. These approaches, consisting of 600 cGy and 150 mg/kg Cy or 400 cGy with 200 mg/kg Cy, were nonmyeloablative and resulted in full donor chimerism. Although the development of GVHD was unpredictable in these transplantation models and varied over experiments (data not shown), 30% of animals succumbed to lethal GVHD within 45 days after transplantation when the inoculum of 3.3 Â 10 7 BM cells was supplemented with 3 or 6 Â 10 7 splenocytes. In later experiments, the radiation dose was divided into two fractions of 200 cGy, separated by a 24 h interval, again in combination with 200 mg/kg Cy. Animals conditioned according to this protocol (n ¼ 7) survived for more than 3 months without administration of BM, indicating that this conditioning regimen is indeed nonmyeloablative. It has to be noted, however, that mice transplanted with 3.3 Â 10 7 BM cells alone did not become chimeric and that the addition of donor splenocytes to the BM inoculum was crucial for inducing engraftment. Although the observation time was limited due to lethal GVHD, animals transplanted with BM and 1 Â 10 8 splenocytes displayed full donor chimerism until death (data not shown). The development of lethal GVHD made this approach suitable for testing the effects of KGF treatment and in all subsequent experiments, the transplantation was performed with this conditioning regimen, consisting of two times 200 cGy and 200 mg/kg Cy.
KGF reduces GVHD symptoms and weight loss after transplantation
We examined whether the administration of KGF had an effect on GVHD-induced symptoms such as weight loss, fur texture and posture. Although control animals succumbing to GVHD (18/19 animals) showed a decrease in body weight before death (residual weight 74.472.5%, n ¼ 18) (data not shown), a remarkable change in weight was already noticed 7 days after transplantation. While animals receiving an allogeneic transplant with PBS had a residual weight of 78.571.4% (n ¼ 19), KGF-treated animals showed a residual weight of 88.471.6% (n ¼ 14) (Po0.0001). Control animals treated with syngeneic BM did not lose weight after transplantation (residual weight 103.471.7%, n ¼ 11), indicating that alloreactive cells in the donor graft are responsible for the weight reduction seen in experimental animals ( Figure 1) .
A number of animals, 11 in the PBS-group and one in the KGF-group, died shortly after transplantation due to severe GVHD-related weight loss. Allogeneic SCT recipients who survived this acute phase of GVHD also displayed differences in skin texture and were therefore compared based on their development of dermatitis. Approximately 3 weeks after transplantation, PBS-treated animals developed a severe, persistent form of dermatitis, corresponding to a score ranging from 1 to 3 (median 3, n ¼ 8), consistent with GVHD. In KGF-treated recipients, dermatitis was either absent at the same time point or reached only a score of 1 (median 1, n ¼ 13) (P ¼ 0.0007). In these cases, dermatitis was indeed very mild and mostly limited to the ears or facial area. Most importantly, KGF-treated animals displayed a transient form of dermatitis, diminishing within 2 weeks after onset. Diarrhea was not a manifest symptom in this model.
KGF decreases injury to the gastrointestinal tract
The finding that KGF was capable of reducing GVHD symptoms after nonmyeloablative conditioning prompted us to investigate whether these effects were due to protection of the GI tract, as it has been reported for a model of lethal irradiation. 32 According to the model described by Ferrara et al, 4 radiation-induced injury to the GI tract induces translocation of LPS into the circulation, leading to a subsequent release of TNF-a. We hypothesized that if KGF would also prevent intestinal injury in a model of nonmyeloablative conditioning, TNF-a levels should diminish. Following the publication of Krijanovski et al, 32 we compared TNF-a values 5 days after syngeneic or allogeneic transplantation, in the latter case combined with PBS or KGF treatment. Initial TNF-a levels, measured before conditioning and transplantation, were below detection level in all groups. PBS-treated animals showed an increase in TNF-a levels to a median of 149.8 pg/ml (range, 69.5-228.8; n ¼ 12), while KGF-treated animals only reached a median value of 50.0 pg/ml (range, 50.0-98.4; n ¼ 11) (P ¼ 0.0008) (Figure 2) . In animals transplanted with syngeneic BM and splenocytes (n ¼ 11), TNF-a levels were undetectable throughout the experiment, indicating that alloreactive cells are necessary for the onset of the GVHD-related cytokine induction in this model, and that the combination of 200 mg/kg Cy and 2 Â 200 cGy irradiation by itself did not induce a measurable elevation of TNF-a levels.
Since it has been demonstrated that citrulline can be used as a marker for radiation-induced injury to the small bowel, 35 we set out to determine the contribution of this amino acid to our transplantation model. Since the plasma citrulline level is highly dependent on the small bowel epithelial cell mass, 36 loss of small intestinal enterocytes will decrease plasma citrulline levels. Citrulline values were compared in four groups of animals, receiving either syngeneic or allogeneic BM and splenocytes, combined with either PBS or KGF treatment. Plasma citrulline values were determined 7 days after transplantation and are presented as a percentage of the baseline value, measured CB6F1 recipient mice were conditioned with two times 200 cGy TBI and 200 mg/kg Cy, and transplanted with syngeneic or allogeneic BM and splenocytes. Allogeneic SCT recipients were treated with PBS or KGF. Plasma TNF-a levels were determined 5 days after transplantation. To calculate statistical significance, values below detection level were set as 50 pg/ml. Combined results from two separate, but identical experiments are shown. (m) Animals treated with syngeneic SCT (n ¼ 11), (') allogeneic SCT þ PBS (n ¼ 12) or () allogeneic SCT þ KGF (n ¼ 11). *P ¼ 0.0008. before conditioning and transplantation. Citrulline levels decreased to 29.1771.59% (n ¼ 17) of the baseline value in PBS-treated controls, whereas in KGF-treated animals, citrulline levels decreased to 72.6273.79% (n ¼ 15) (Po0.0001). Animals that received a syngeneic transplant, combined with PBS or KGF displayed increased citrulline levels of 160.0714.9% (n ¼ 5) and 116.375.83% (n ¼ 5) respectively (Figure 3a) .
To confirm these results, four to five animals from each group were killed 7 days after transplantation for histologic examination of the small bowel (Figure 4) .
Animals that received a syngeneic transplant showed almost no necrosis (0.2570.25; n ¼ 4) and animals that received this transplant in combination with KGF treatment displayed minimal single-cell necrosis (1.6070.24; n ¼ 5). After allogeneic transplantation, single-cell necrosis reached a score of 3.8070.20 (n ¼ 5) in PBS-treated animals, while the necrosis in the animals treated with KGF was decreased to a score of 1.8070.20 (n ¼ 5) (P ¼ 0.0001), comparable to the level in syngeneicallytransplanted animals treated with KGF.
Morphometric analysis of the histologic slides revealed a mucosal surface with a median value of 13.75 mm (range, 12.10-24.60; n ¼ 4) and 16.10 mm (range, 14.00-16.50; n ¼ 3) in animals receiving a syngeneic transplant in combination with PBS or KGF treatment, respectively. After allogeneic transplantation, the mucosal surface decreased to a median value of 10.55 mm (range, 9.80-11.40; n ¼ 4) in PBS-treated animals, whereas in KGF-treated mice, a median value of 13.20 mm (range, 10.12-17.20; n ¼ 4) was measured (P ¼ 0.105) (Figure 3b ). Although these results did not reach statistical significance due to the limited number of animals, we were able to confirm our previous findings and demonstrated a correlation between the mucosal surface and the plasma citrulline levels 7 days after transplantation (r ¼ 0.595, P ¼ 0.019, n ¼ 15).
KGF increases survival
In view of the fact that KGF was capable of reducing GVHD symptoms directly after transplantation, we hypothesized this effect might have long-term advantages leading to an increased survival ratio. Therefore, survival was monitored for 200 days after transplantation, in mice receiving either PBS or 5 mg/kg KGF from 3 days before conditioning till 3 days after transplantation. The survival curves represent the sum of three experiments ( Figure 5) .
In animals treated with KGF overall survival was much higher than in the PBS-treated controls (P ¼ 0.0002). Whereas animals receiving PBS (n ¼ 19) had a survival of 5.3% 200 days after transplantation, KGF-treated mice (n ¼ 14) still showed a survival of 57.1% (P ¼ 0.0042).
KGF permits sustained multilineage chimerism
At various time points (1, 3 and 6 months) after haploidentical transplantation, control-and KGF-treated mice were tested for the presence of donor immune cells in the blood. Animals in both groups were full donor chimeras until death and chimerism was present in the T-and B-cell lineage. In KGF-treated mice, surviving the haploidentical transplantation for an extended period of time (n ¼ 9), T-and B-cells were still of donor origin 200 days after allogeneic transplantation ( Figure 6 ). This indicates that the engraftment of haploidentical donor cells, induced with a nonmyeloablative conditioning regimen, is not hampered by KGF treatment.
Discussion
In this paper, we describe a mouse model of allogeneic SCT in which conditioning is nonmyeloablative and donors and recipients are fully haploidentical. Whereas others often use P-F1 combinations, we prefer using a F1-F1 model as it is more similar to the clinical situation, where in haploidentical transplantations patient and donor share one haplotype and are mismatched for the other. This difference is relevant since immune factors might be present in both the host-versus-graft (graft rejection) as well as the graft-versus-host direction (GVHD and anti-tumor effect), irrespective of the cells involved. In developing our haploidentical transplantation model, we pursued the aims of nonlethal conditioning, long-term chimerism and the prevention of lethal GVHD by means of KGF. Titration of radio-and chemotherapy doses yielded several nonmyeloablative preparative regimens leading to full donor chimeras, with 400 cGy of TBI and 200 mg/kg Cy being the least toxic strategy. Ultimately, we replaced the initial radiation of 400 cGy with a radiation schedule of two times 200 cGy. This definite model, consisting of two times 200 cGy TBI, 200 mg/kg Cy and a BM inoculum of 3.3 Â 10 7 cells was nonmyeloablative and nontoxic with 100% survival in all syngeneic controls performed thus far.
Nevertheless, we noticed that in our particular experimental situation, splenocytes were crucial for the induction of stable multilineage chimerism and GVHD. Mice transplanted with BM cells alone did not become chimeric and failed to develop GVHD, which can be explained by the amount of T cells present in the donor inoculum. Analyses of various BM samples of B6CBAF1 donor mice showed a T cell content of 2.08% (range, 1.26-3.87; n ¼ 5) compared to 38.55% (range, 31.14-49.35; n ¼ 5) in the spleen. These results are in accordance with the observations in C57BL6 mice where T cells make up only 1 to 3% of all BM cells. 37 Analyses of T cell subsets revealed that bone marrow contains only 0.78% (range, 0.56-0.91; n ¼ 3) CD4 þ T cells as opposed to 25.22% (range, 21.87-35.66; n ¼ 5) in splenocyte suspensions. It has been demonstrated previously that marrow CD4 þ and CD8 þ T cells failed to induce GVHD, even at high numbers, while peripheral CD4 þ T cells have been proven to be potent inducers of lethal GHVD. 38 Since adding spleen cells to the BM inoculum did induce high rates of lethal GVHD in our model, we studied the effect of KGF on the development of GVHD. We demonstrated that KGF treatment resulted in reduced GVHD and superior survival. To our knowledge, this is the first report describing a positive effect of KGF on GVHD in a nonmyeloablative conditioning regimen. The use of KGF as GVHD prophylaxis has been documented in studies using lethal conditioning regimens with mismatched 31 or P-F1 donor-recipient pairs. 32 In our haploidentical mouse model, animals treated with KGF showed a much lower post-transplant weight reduction than their saline-treated counterparts. Moreover, KGFtreated mice developed a mild and transient form of dermatitis, whereas control-treated animals suffered from severe, persistent dermatitis, covering the entire body. Long-term effects of KGF manifested themselves as an improved survival ratio in KGF-treated animals compared to controls.
Additional proof of beneficial KGF effects on the development of GVHD was provided by analysis of murine plasma for TNF-a. As conditioning induces damage to and activation of the intestinal mucosa, leading to a release of inflammatory cytokines such as TNF-a 4 , KGF can be used as a shield to interrupt the cytokine cascade and protect the gut epithelium. 39 Indeed, when animals were treated with 5 mg/kg KGF for 9 consecutive days, plasma TNF-a levels were significantly lower than in control-treated animals. These results, measured 5 days after allogeneic transplantation, are in accordance with the findings in a radiation-based P-F1 transplantation model 32 and are indicative of reduced GI damage, due to a combination of conditioning and allogeneic transplantation.
However, our observations differ partly from the theory that conditioning-induced cytokine release is responsible for the subsequent development of GVHD. In this nonmyeloablative model, we did not observe a measurable elevation of TNF-a levels in syngeneic controls, as is the case after myeloablative TBI. However, local cytokine release, even when it is not quantifiable, cannot be ruled out as a contributing factor in the pathophysiology of GVHD. Reduced TNF-a levels observed after KGF treatment might also reflect reduced GVHD rather then conditioning-induced damage alone. It is also possible that other cytokines, inflammatory as well as anti-inflammatory 30, 40 play a role in the protective mechanism of KGF in our transplantation model. In our opinion, however, the most relevant observation is that KGF also protects from GVHD after nonmyeloablative conditioning regimens in a haploidentical setting.
To determine whether KGF does in fact mediate its positive effect through protection of the GI tract, we measured plasma citrulline concentrations 1 week after transplantation. Recently, several reports have demonstrated that citrulline can be used as a quantitative marker for radiation-induced small bowel injury. 35, 41, 42 Reduction of small bowel epithelial cell mass through surgery or ionizing radiation is associated with diminished plasma citrulline levels, as demonstrated in rodents 35, 43, 44 and patients. 45 In the present study, we demonstrated that plasma citrulline levels decreased by almost 75% 1 week after allogeneic transplantation and that KGF treatment was able to diminish this effect. Control animals treated with a syngeneic transplant and PBS showed elevated citrulline levels, consistent with previous observations in patients in response to radiation treatment. 41 Histologic sections of the small bowel were compared to confirm the previously established relationship between citrulline values and small intestinal damage. We found that after allogeneic transplantation, small intestinal damage as measured by single-cell necrosis and mucosal surface, was lower in KGF-treated animals than in PBStreated controls. It has to be noted, however, that in our experiments of nonmyeloablative conditioning, overall damage was mild compared to earlier publications where animals were conditioned more intensely. 32, 46 Animals that received the nonmyeloablative conditioning regimen as a preparation for the syngeneic transplant showed almost no damage to the GI tract, indicating that most of the necrosis in our model is a result of the development of GVHD. In animals treated with KGF in combination with a syngeneic transplant, single-cell necrosis was slightly higher than in the PBS-treated counterparts, probably due to a toxic effect of the growth factor. However, this elevation in necrotic score does not seem to interfere with the positive effect KGF has in the allogeneic situation. Taken together, our data indicate that protection of the gut mucosa is the most likely pathway of KGF in GVHD prevention, although a protective effect of KGF on other GVHD target organs through effector immune cells cannot be ruled out.
Since KGF considerably improved survival of animals transplanted with allogeneic BM, this treatment will give us the opportunity to study anti-tumor effects in this mouse model. At present, studies are being performed to analyze the anti-tumor effect of these haploidentical transplantations on both solid tumors as well as hematological malignancies. Although not as GVHD prophylaxis, KGF has already been applied in clinical trials. When used for the treatment of oral mucositis, KGF was well tolerated by patients, only some mild skin and oral adverse effects occurred. 25, 47 In our animal model, mice exhibited roughened hair for the duration of the KGF treatment. This might be explained by the overall effect of KGF on all epithelial elements, including hair follicles. 26, 48 It is worth mentioning that this fur condition is only temporary and returns to normal within a few days after cessation of the treatment. Considering this mild side effect, the effect on the small intestine and taking into account some reports about KGF post-treatment not adding to overall survival, 46 ,31 it might be wise to examine whether a short pretransplant KGF treatment is sufficient to prevent lethal GVHD in our setting.
Haploidentical transplantations in man are not yet a frequently performed clinical procedure and the combination with nonmyeloablative conditioning has only been described in some case reports 8, 10 and smaller studies. 12 However, the anti-tumor effects that were demonstrated in these models of hematological and solid tumors make this approach an attractive option for clinical cancer treatment. Recent publications 16, 24 indicate the feasibility of haploidentical transplantations in terms of GVHD prevention and antileukemia effects. Unfortunately, the haploidentical procedure leads to severe immunodeficiency, mainly because of strong T cell depletion necessary to prevent acute GVHD. If KGF could play a positive role in GVHD prevention in clinical haploidentical models, it would allow for more T cells to be transplanted. It has been shown that donor T cells are indeed crucial for recovery of immune function after haploidentical transplantations. 49 Adding KGF treatment to haploidentical transplantations, possibly in combination with standard GVHD prophylaxis, 50 might therefore be a valuable clinical option, allowing more transplantations to be performed safely without serious GVHD and immunodeficiency.
In conclusion, the present study demonstrates that in a model of nonmyeloablative haploidentical transplantation KGF is able to significantly increase overall survival by preserving gut integrity. In addition, our data support the development of clinical trials in haploidentical transplantation regimens, with add-back of increased amounts of T cells.
